SCHEMBL109301

SCHEMBL109301

CSNCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
IDO1 P14902 3/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
THRB P10828 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 3/20 0.45
CA2 P00918 3/20 0.45
CA1 P00915 2/20 0.45
CA9 Q16790 2/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
ADH1B P00325 1/20 0.43
ADH1C P00326 1/20 0.43
ADH1A P07327 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10435079 0.98 MAPT (0.56) CYP3A4MAPTKDM4EIDO1MEN1
SCHEMBL11360130 0.79 IDO1 (0.52) CYP3A4MAPTKDM4EIDO1MEN1
Hydrochlorthiazide SCHEMBL28652724 0.79 IDO1 (0.36) CYP3A4MAPTKDM4EIDO1MEN1
SCHEMBL19393059 0.78 LOXL2 (0.56) CYP3A4MAPTKDM4EMEN1KMT2A
SCHEMBL24335030 0.76 ALDH1A1 (0.44) CYP3A4KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL24497367 0.76 CYP3A4 (0.48) CYP3A4MAPTKDM4EIDO1MEN1
SCHEMBL11151821 0.76 ATM (0.58) CYP3A4MAPTIDO1MEN1KMT2A
SCHEMBL21034357 0.75 IDO1 (0.48) CYP3A4MAPTKDM4EIDO1MEN1
SCHEMBL8075682 0.75 IDO1 (0.54) CYP3A4MAPTKDM4EIDO1MEN1
SCHEMBL5355705 0.75 IDO1 (0.48) CYP3A4MAPTKDM4EIDO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
CN-116444454-A N-hydroxy amidine derivative, preparation method and application thereof, and tumor immunotherapy medicament 中国医学科学院医药生物技术研究所 2023-07-18 CN disclosed
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors Nanjing Immunophage Biotech Co., Ltd. (CN) 2023-02-09 US disclosed
US-10730870-B2 Compounds and methods for the enhanced degradation of targeted proteins ARVINAS OPERATIONS, INC. (US) 2020-08-04 US disclosed
US-20190092851-A1 ANTIBODY MOLECULES TO APRIL AND USES THEREOF Visterra, Inc. 2019-03-28 US disclosed
EP-2424874-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-03-07 EP disclosed
WO-2010125200-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-11-04 WO disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
EP-1608643-A1 6-SULFONAMIDE QUINOLINE AND CHROMENE DERIVATIVE AS ANDROGEN RECEPTOR ANTAGONISTS Warner-Lambert Company LLC (US) 2005-12-28 EP disclosed
US-20050245508-A1 Treatment of malignant gliomas with TGF-beta inhibitors SCIOS, INC. (US) 2005-11-03 US disclosed
WO-2004083204-A1 6-SULFONAMIDE QUINOLINE AND CHROMENE DERIVATIVE AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-09-30 WO disclosed
US-4478833-A ANTICOAGULANTS DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1984-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245508-A1 Treatment of malignant gliomas with TGF-beta inhibitors TGFBR1, TGFBR2, SMAD3 CYP3A4 4629/4885MAPT 2319/4885KDM4E 814/4885
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT CYP3A4 2422/4885MAPT 582/4885KDM4E 2846/4885
US-10730870-B2 Compounds and methods for the enhanced degradation of targeted proteins VHL, MDM2, XIAP CYP3A4 4113/4885MAPT 2786/4885KDM4E 1271/4885
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors CCR8, CCR1, CCR3 CYP3A4 2832/4885MAPT 4016/4885KDM4E 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.